Washington, D.C. – Congressman Michael C. Burgess, M.D. (R-TX), Vice Chairman of the House Rules Committee, released the following statement in response to the Biden Administration’s announcement of the first ten drugs selected for Medicare price negotiation.

"The so-called 'Inflation Reduction Act' mandates the Centers for Medicare & Medicaid Services (CMS) to negotiate drug prices. However, it's crucial to recognize that this administration's approach goes beyond 'negotiation.' Instead, it holds pharmaceutical companies hostage, jeopardizing their future innovation and the well-being of American patients,” said Burgess. “This hasty move not only threatens access to medicines for American seniors but also introduces unnecessary barriers to their healthcare choices, including heavy restrictions and potential discontinuation of vital medications under Medicare Part D. The looming threat of government-imposed price controls raises concerns about worsening drug shortages, especially within the generic market. The consequences extend to stifling research and investment in life-saving treatments, undermining America's global leadership in biopharmaceutical innovation. Awaiting court decisions rather than taking precipitous actions is essential to safeguarding patient care, innovation, and our economy."